Search Results - "Schalekamp, T"

Pharmacogenetics: From Bench to Byte- An Update of Guidelines by Swen, JJ, Nijenhuis, M, Boer, A, Grandia, L, Maitland‐van der Zee, AH, Mulder, H, Rongen, GAPJM, Schaik, RHN, Schalekamp, T, Touw, DJ, Weide, J, Wilffert, B, Deneer, VHM, Guchelaar, H‐J

“…Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch…”
Get full text

Pharmacogenetics of oral anticoagulant therapy by Schalekamp, Tom, de Boer, Anthonius

“…The identification of the genes encoding CYP2C9, the principal metabolizing enzyme of the coumarins, and VKORC1, the molecular target for coumarins, has…”
Get more information

VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement by Schalekamp, T, Brassé, B P, Roijers, J F M, Meegen, E, Meer, F J M, Wijk, E M, Egberts, A C G, Boer, A

“…In a prospective follow‐up study of the effects of VKORC1 and CYP2C9 genotypes on the anticoagulation status of patients, we assessed the CYP2C9 and the VKORC1…”
Get full text

Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon by Becker, M. L., Franken, W. P. J., Karapinar, F., Verzijl-Zeegers, R., Schalekamp, T., van der Hoeven, R. T. M.

“…Purpose It is established that omeprazole increases (R)+ warfarin levels with around 10 %. Whether (es)omeprazole also increase the plasma levels of…”
Get full text

Long‐term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users by VERHOEF, T. I., REDEKOP, W. K., BUIKEMA, M. M., SCHALEKAMP, T., VAN DER MEER, F. J. M., LE CESSIE, S, WESSELS, J. A. M., VAN SCHIE, R. M. F., DE BOER, A., TEICHERT, M., VISSER, L. E., MAITLAND‐VAN DER ZEE, A. H.

“…Background:  The required acenocoumarol dose and the risk of underanticoagulation and overanticoagulation are associated with the CYP2C9 and VKORC1 genotypes…”
Get full text

An evaluation of gene–gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol by VAN SCHIE, R. M. F., BABAJEFF, A. M. V., SCHALEKAMP, T., WESSELS, J. A. M., LE CESSIE, S., de BOER, A., VAN DER MEER, F. J. M., VAN MEEGEN, E., VERHOEF, T. I., ROSENDAAL, F. R., MAITLAND‐VAN DER ZEE, A. H.

“…Background:  Previous studies have provided contradictory results regarding the interaction between the CYP2C9 and VKORC1 genotypes affecting various outcome…”
Get full text

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status by Schalekamp, Tom, Oosterhof, Mirjam, Meegen, Erik, Der Meer, Felix J. M., Conemans, Jean, Hermans, Mirjam, Meijerman, Irma, Boer, Anthonius

“…Objective Our objective was to assess whether there is an association between the presence of allelic variants of the gene for cytochrome P450 (CYP) 2C9 and…”
Get full text

CYP2C9 genotyping in acenocoumarol treatment: Is it a cost‐effective addition to international normalized ratio monitoring? by Schalekamp, Tom, Boink, Gerard J.J., Visser, Loes E., Stricker, Bruno H. Ch, Boer, Anthonius, Klungel, Olaf H.

Get full text

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation by SCHALEKAMP, T, BRASSE, B, ROIJERS, J, CHAHID, Y, VANGEESTDAALDEROP, J, DEVRIESGOLDSCHMEDING, H, VANWIJK, E, EGBERTS, A, DEBOER, A

Get full text

Reply by SCHALEKAMP, T, DEBOER, A

Get full text

Acenocoumarol Stabilization is Delayed in CYP2C93 Carriers by Schalekamp, Tom, Geest‐Daalderop, Johanna H. H., Vries‐Goldschmeding, Hanneke, Conemans, Jean, Bernsen, M. J., Boer, Anthonius

“…Objective Our objective was to assess whether there is an association between the presence of allelic variants of the gene for cytochrome P450 (CYP) 2C9 and…”
Get full text

Potential determinants of drug-drug interaction associated dispensing in community pharmacies by BECKER, Matthijs L, KALLEWAARD, Marion, CASPERS, Peter W. J, SCHALEKAMP, Tom, STRICKER, Bruno H. C

“…Although the number of clinically relevant drug-drug interactions (DDIs) is probably low, DDIs may be responsible for a substantial number of hospital…”
Get full text

Rifampicin less effective for a long time after use of coumarin derivatives by Schalekamp, T, Horikx, A

Get more information

Suboptimal choices and dosing of statins at start of therapy by Mantel‐Teeuwisse, Aukje K., Klungel, Olaf H., Schalekamp, Tom, Verschuren, W. M. Monique, Porsius, Arijan J., De Boer, Anthonius

“…Aim To assess dosing and determinants of the choice of statins among starters of statins. Methods Data were obtained from the PHARMO database comprising…”
Get full text

Deterioration of schizoaffective disorder due to an interaction between haloperidol and carbamazepine by Schalekamp, T

Get more information

Determination of phenol in the presence of resorcinol applying substitution with excess bromine water; structure of the bromination products by Dreijer-Van Der Glas, S M, Schalekamp, T, De Jong, H J, Bult, A

“…Bromination with a large excess of bromine results in the formation of a tetrabromo product for phenol and a pentabromo derivative for resorcinol. It is…”
Get more information